Internal Med

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Johnson S et al. - Current guidelines recommend that the first recurrent episode be treated with the same agent (i.e., metronidazole or vancomycin) used for the index episode. A reasonable strategy for managing a subsequent episode involves tapering followed by pulsed doses of vancomycin. Other potentially effective strategies for recurrent CDI include vancomycin with adjunctive treatments, such as Saccharomyces boulardii, rifaximin “chaser” therapy after vancomycin, nitazoxanide, fecal transplantation, and intravenous immunoglobulin. New treatment agents that are active against C. difficile, but spare critical components of the normal flora, may decrease the incidence of recurrent CDI.

   

Related Articles

Toxigenic Clostridium difficile colonization in children
Journal of Pediatric Infectious Diseases, 10/30/09    Relevance Score: 68%

Molecular Epidemiology of Clostridium difficile over the Course of 10 Years in a Tertiary Care Hospital
Clinical Infectious Diseases, 10/16/09    Relevance Score: 67%

Clostridium difficile-related death rates in Texas 1999-2005
Journal of Infection, 10/06/09    Relevance Score: 67%

Bacteriophage-Mediated Toxin Gene Regulation in Clostridium difficile
Journal of Virology, 11/09/09    Relevance Score: 66%

Use of International Classification of Diseases, Ninth Revision, Clinical Modification Codes and Medication Use Data to Identify Nosocomial Clostridium difficile Infection
Infection Control and Hospital Epidemiology, 10/14/09    Relevance Score: 66%

Today in Clinical Pharmacology...keeping you current

Resorption and elimination kinetics of benzoic acid during chemical necrectomy in deep burns
Scandinavian Journal of Clinical and Laboratory Investigation, 12/19/09

Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia
Haematologica, 12/18/09

Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
Journal of Clinical Oncology, 12/18/09